stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Revenue growth
Xencor, Inc.'s revenue growth over the twelve months to 30 June 2026 was −28.6%, down 42.2 percentage points from fiscal 2025 (13.7%). Over the past ten years it has ranged from −57.7% (fiscal 2017) to 292.7% (fiscal 2016); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 13.7% | 50.37 |
| FY2024 | −36.7% | (42.82) |
| FY2023 | 6.10% | 46.28 |
| FY2022 | −40.2% | (164.41) |
| FY2021 | 124.2% | 145.93 |
| FY2020 | −21.7% | (307.63) |
| FY2019 | 285.9% | 297.95 |
| FY2018 | −12.0% | 45.65 |
| FY2017 | −57.7% | (350.37) |
| FY2016 | 292.7% | 101.08 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 17.5% | 103.66 |
| Mar 2026 | −86.2% | (39.69) |
| Dec 2025 | −46.5% | (64.51) |
| Sep 2025 | 18.0% | (64.41) |
| 39 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BEAM Beam Therapeutics Inc. compare | 163.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 56.2% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.02% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −26.4% |
| XNCR Xencor, Inc. | −28.6% |
| RCUS Arcus Biosciences, Inc. compare | −58.3% |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement